The first of nearly 3,000 lawsuits over the diabetes drug Actos has gone to trial, with the attorney for a 78-year-old man who now has bladder cancer claiming that the manufacturer of the blockbuster drug, Takeda Pharmaceuticals, failed to warn doctors of the cancer risk associated with the drug.
In opening statements at a Los Angeles state court, the plaintiff’s attorney told the jury that his client’s doctor was never told about bladder cancer risks associated with Actos during any of the alleged 195 visits company representatives made to the physician’s office to discuss Takeda’s products. Read the rest »
A new study published in the British Medical Journal (BMJ) is reporting that use of the drug pioglitazone – better known by its brand name, Actos — is associated with an increased risk of bladder cancer.
Although the drug currently carries a warning about increased risks of bladder cancer, this new study suggests that the risk may be greater than was previously believed.
A research team studied the medical records of more than 115,000 diabetes patients in Great Britain. What they found was that patients who had ever taken Actos had an 83 percent increased risk of bladder cancer. That risk doubled for those patients who took the drug for more than two years and took higher doses. Read the rest »
A medical reviewer who worked for the manufacturer of the drug Actos, has filed a whistleblower lawsuit claiming that the drug company knowingly hid adverse events associated with the embattled diabetes drug.
The lawsuit alleges that Takeda Pharmaceuticals North America, Inc., concealed Actos heart failure risks. The suit goes on to contend that as a result of the concealment, doctors prescribed the drug more than they would have had they known the risks, which ultimately cost federal and state health programs hundreds of millions of dollars. Read the rest »
Actos is a diabetes medication that is the subject of hundreds, if not thousands, of lawsuits. The problem is that when Actos, also known as pioglitazone, is used for a prolonged time period it is found to increase the risk of developing bladder cancer. In France, the sales of Actos have been suspended and sales are seriously curtailed in Germany, but Actos is still sold in the U.S. despite some pretty serious U.S. Food and Drug Administration (FDA) warnings.
In the U.S., the drug was considered a blockbuster, delivering record profits to Japanese drugmaker Takeda Pharmaceutical Industries with $2.5 billion in sales in 2010. An American subsidiary, Takeda Pharmaceuticals North America (based in Illinois), is now where a number of lawsuits have been filed and should be heard. Read the rest »
Last month, the outstanding Actos lawsuits pending in federal courts around the country were consolidated before Judge Rebecca F. Doherty in U.S. District Court for the Western District of Louisiana. That decision was made by the U.S. Judicial Panel on Multidistrict Litigation (JPML), a federal panel that decides how to handle the massive number of personal injury cases that result from the same defective product. The JPML determined there were common questions of law among the thousands of plaintiffs to merit the consolidation of pretrial proceedings. This saves plaintiffs money in that their lawyers can all share information gathered from Asian drug maker Takeda Pharmaceutical Co. and its co-defendant, Eli Lilly & Co.
A question yet to be answered is whether the drug maker and distributor withheld adequate warning from doctors and consumers, thereby failing to give users informed consent about the potential risk for bladder cancer. Read the rest »
Public Citizen, in its Worst Pills, Best Pills publication, reports that on August 4, 2011, the U.S. Food and Drug Administration (FDA) revised the warning on the type 2 diabetes drug, Actos, to include a warning about an increased risk of Actos bladder cancer. Actos, made by Takeda Pharmaceuticals, is also known as pioglitazone. It is available as a standalone drug, or can be combined with the diabetes drug metformin or with glimepiride.
It wasn’t that long ago that another drug in the same family, Rezulin, was taken off the market because of living toxicity. Actos is also part of the same family, which also includes Avandia, and it can carry an elevated risk of heart attack and failure, as well as eye abnormalities and bone fractures. Even before the bladder cancer risk was known, the advocacy group Public Citizen had put Actos on its ”Do Not Use” list because the risks seemed to outweigh the benefits, especially considering there are longer term and safer drugs available such as metformin (Glucophage). Read the rest »